Joseph Larsen
Foot & Ankle Surgery · Garden City Park, NYNPI 1629193941
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Musculoskeletal Transplant Foundation Inc. at 59.7% of the total. Reporting peaked in 2023 at $23,145 and has fallen 72.6% since, to $6,336 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $249.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Musculoskeletal Transplant Foundation Inc.$54K
- Royal Biologics, Inc.$19K
- Gramercy Extremity Orthopedics LLC$6K
- Next Science LLC$3K
- Polynovo North America LLC$2K
- Acera Surgical, Inc.$1K
- plus $6K from 29 others
Across 1 payment — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Royal Biologics, Inc.$3K
What the payments were for
- Royalty or licence$6031%
- Consulting fees$51,19157%
- Travel & lodging$14,24316%
- Food & beverage$23,52126%
- Entertainment$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Musculoskeletal Transplant Foundation Inc. | 110 | $53,604 |
| Royal Biologics, Inc. | 43 | $18,506 |
| Gramercy Extremity Orthopedics LLC | 15 | $5,637 |
| Next Science LLC | 42 | $3,108 |
| Polynovo North America LLC | 47 | $2,185 |
| Acera Surgical, Inc. | 9 | $1,082 |
| Medline Industries LP | 5 | $641 |
| Medshape, Inc. | 5 | $605 |
| Organogenesis Inc. | 4 | $453 |
| DJO, LLC | 7 | $406 |
| Stryker(2 entities) | 5 | $393 |
| Treace Medical Concepts, Inc. | 7 | $353 |
| Encore Medical, LP | 2 | $343 |
| Orthofix Medical, Inc. | 6 | $325 |
| Trilliant Surgical LLC. | 2 | $310 |
| In2bones USA, LLC | 4 | $269 |
| Novastep Inc. | 1 | $184 |
| Integra Lifesciences Corporation | 4 | $181 |
| AbbVie(2 entities) | 7 | $144 |
| Boston Scientific | 1 | $141 |
| Baxter Healthcare | 3 | $137 |
| Smith+Nephew | 5 | $131 |
| Stability Biologics, LLC | 1 | $127 |
| Lifenet Health | 6 | $96 |
| Tactile Systems Technology Inc | 6 | $92 |
| Paragon 28, Inc. | 1 | $48 |
| Zimmer Biomet | 1 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Sebela Pharmaceuticals Inc. | 1 | $30 |
| IBSA Pharma Inc. | 1 | $22 |
| Polaris Technology Solutions LLC | 1 | $22 |
| Merck | 1 | $19 |
| Bioventus LLC | 1 | $16 |
| Reprise Biomedical, Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fibrinet$6,454
- AmnioMaxx$3,830
- MaxxCell$2,765
- Xperience$2,419
- BlastX$2,419
- SurgX$1,957
- Novosorb BTM$1,657
- Restrata Wound Matrix$964
- CryoCord$524
- DynaClip Bone Fixation System, Quattro, 22mm x 20mm x 20mm$292
- DynaNail Helix, Washer, 15 mm$288
- Maxx Cell$252
- Apligraf$227
- PuraPly$226
- CITREFIX$222
- CREED Ortholocent Implants$184
- Physio-Stim$183
- Arsenal Ankle 10 Hole 1/3 Tubular Plate$166
- Hyalomatrix Wound Device$161
- Amnio Maxx$147
How this compares
$89,718 in reported general payments places this provider in the 95th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diflorasone Diacetate | 25 | $24,207 |
| Oxiconazole Nitrate | 39 | $22,096 |
| Halobetasol Propionate | 39 | $5,521 |
| Fluocinonide | 14 | $1,856 |
| Clotrimazole | 20 | $1,387 |
| Ketoconazole | 23 | $1,373 |
| Naproxen | 21 | $954 |
| CiclopiroxCiclopirox Olamine | 20 | $781 |
| Terbinafine Hcl | 15 | $309 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $244 |
| Mupirocin | 14 | $123 |
| Levofloxacin | 18 | $98 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $88 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Garden City Park
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$597K
- John KennedyNew York$534K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$328K
- Stuart MogulNew York$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.